1. Scrip
  2. >>Therapy Areas

AbbVie Validates Voyager’s One-Shot Approach With Parkinson’s Collaboration

 
• By Jo Shorthouse

AbbVie and existing partner Voyager Therapeutics are attempting to cross the blood-brain barrier with a new collaboration on vectorized antibodies to treat Parkinson’s disease and other synucleinopathies such as Lewy body dementia and multiple system atrophy.  

HandsBrain
• Source: Shutterstock

Voyager Therapeutics Inc. has received another important validation for its CNS gene therapy approach by signing a collaboration with existing partner AbbVie Inc. on Feb. 22 that will see the pair develop and commercialize "vectorized antibodies" for Parkinson's disease and other diseases characterized by the abnormal accumulation of misfolded alpha-synuclein protein.

Several analysts are encouraged by this deal, with BTIG stating that it could lead to the “first true

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

More from Therapy Areas

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.